Back to top
more

Better trading starts here.

Brokerage Reports

Research for GNFT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

4 items in cart

View Cart/Checkout

GENFIT S.A. Unsponsored ADR [GNFT]

Reports for Purchase

Showing records 61 - 80 ( 117 total )

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 61

01/10/2020

Industry Report

Pages: 11

Healthcare Join Our 1Q20 Doc Call Series

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 62

01/06/2020

Industry Report

Pages: 14

NASH Weekly: 2020 Is Packed With Clinical Data Readouts in NASH

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 50.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 63

01/03/2020

Industry Report

Pages: 17

NASH Weekly: GLP-1 Data in 2Q20 Is Likely to Be Underwhelming

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 50.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 64

12/27/2019

Industry Report

Pages: 3

Yas'' Weekly Recap of Our Key Notes

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 65

12/26/2019

Industry Report

Pages: 10

As we are three weeks away from JPM Healthcare conference.

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 66

12/20/2019

Industry Report

Pages: 3

Healthcare - Yas'' Weekly Recap of Our Key Notes

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 67

12/19/2019

Company Report

Pages: 9

Unlocking the Power of Non-Invasive NASH Diagnosis - Must Read

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 68

12/19/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 69

12/16/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 70

12/13/2019

Company Report

Pages: 9

Takeaway Note with PPAR Guru, Dr. Bart Staels

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 71

12/13/2019

Industry Report

Pages: 2

Yas'' Weekly Recap of Our Key Notes and Upcoming Events

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 72

12/12/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 73

12/12/2019

Company Report

Pages: 8

Join Our Call at 12:30 PM Today to Figure Out POS for RESOLVE-IT

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 74

12/11/2019

Daily Note

Pages: 2

Healthcare Expert Call Recap for 2019 in NASH and Liver Disease

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 75

12/05/2019

Industry Report

Pages: 11

Why You Can''t Miss Our Four Doc Calls on mRNA, PPAR, Hyperoxaluria, Acromegaly

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 76

11/29/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 77

11/27/2019

Company Report

Pages: 9

Join our Call Series to Connect the Dots on NASH Biology - Diagnosis

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 78

11/27/2019

Company Report

Pages: 8

Emerges Unscathed from the PPAR Fog

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 79

11/26/2019

Daily Note

Pages: 5

Another ''All Clear'' on Elafibranor From DSMB

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: GENFIT S.A. Unsponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 80

11/25/2019

Industry Report

Pages: 8

Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party